F8 and hemophilia: The finding that inhibitor development was reduced in patients treated with EHL-FVIII is corroborated by EUHASS analyses in severe PTPs (IRR, 0.12; 95% CI, <0.01 to 0.70; P < .01) but not in PUPs with severe hemophilia where inhibitor development on EHL-FVIII was similar to that on SHL-FVIII at (22.2% vs 26.9%; OR, 0.78; 95% CI, 0.40-1.50; P =.45) [3,10].